IE 11 is not supported. For an optimal experience visit our site on another browser.

Drug maker expects approval for Plan B

The chief executive of Barr Pharmaceuticals Inc. said that U.S. regulators were likely to grant conditional approval in May for the controversial over-the-counter switch of the morning-after pill.
/ Source: Reuters

The chief executive of Barr Pharmaceuticals Inc. said Wednesday that U.S. regulators were likely to grant conditional approval in May for the controversial over-the-counter switch of the morning-after pill.

The U.S. Food and Drug Administration said in February it would postpone a decision on the switch to non-prescription status from prescription status for the contraceptive until May 21.

Barr Chief Executive Bruce Downey said in a quarterly conference call on Wednesday that he expects conditional FDA approval, but not final approval, by that time. But he said he expects that only negotiations on the language of the label --typically a short delay -- would hold up full approval for the switch.